Cellectis S.A. (CLLS) has a negative trailing P/E of -5.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -19.28%.
Criteria proven by this page:
Overall SharesGrow Score: 47/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -9.4 | -0.05 | 2.20 | 14.05 | - |
| 2017 | -10.8 | -0.20 | 4.03 | 42.64 | - |
| 2018 | -8.6 | 0.28 | 1.66 | 53.32 | - |
| 2019 | -7.1 | -0.65 | 2.31 | 47.83 | - |
| 2020 | -14.2 | 0.71 | 4.05 | 22.53 | - |
| 2021 | -3.2 | -0.25 | 1.64 | 11.99 | - |
| 2022 | -0.9 | -0.04 | 0.81 | 4.99 | - |
| 2023 | -1.7 | 0.07 | 2.07 | 232.58 | - |
| 2024 | -4.4 | 0.06 | 1.24 | 3.93 | - |
| 2025 | -7.2 | -0.11 | 6.39 | 6.63 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1.78 | $42.58M | $-63.92M | -150.1% |
| 2017 | $-2.78 | $25.19M | $-99.37M | -394.5% |
| 2018 | $-1.93 | $12.73M | $-78.69M | -618.1% |
| 2019 | $-2.14 | $15.19M | $-90.69M | -597% |
| 2020 | $-1.71 | $73.95M | $-72.57M | -98.1% |
| 2021 | $-1.93 | $73.95M | $-86.28M | -116.7% |
| 2022 | $-2.17 | $19.17M | $-98.69M | -514.8% |
| 2023 | $-1.77 | $755K | $-101.06M | -13385.3% |
| 2024 | $-0.37 | $41.51M | $-36.76M | -88.6% |
| 2025 | $-0.68 | $73.17M | $-67.8M | -92.7% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.09 | $-1.19 – $-1.00 | $61.17M | $41.02M – $72.82M | 5 |
| 2027 | $-0.85 | $-2.25 – $1.89 | $119.05M | $24.31M – $354.35M | 4 |
| 2028 | $-1.14 | $-3.21 – $-0.19 | $76.86M | $27.44M – $183.8M | 3 |
| 2029 | $-1.39 | $-3.89 – $-0.23 | $75.3M | $26.88M – $180.06M | 2 |
| 2030 | $-1.17 | $-3.27 – $-0.19 | $159.45M | $56.92M – $381.29M | 2 |
